Opioid-Induced Hypogonadism in the United States.

ABSTRACT:

Objective

To examine the incidence of screening, diagnosis, and treatment of hypogonadism among men treated with opioids in the United States.

Patients and methods

Using one of the nation's largest commercial insurance databases, we identified 53,888 men aged 20 years or older who had 90 or more days of opioid prescriptions in a single 12-month period between January 1, 2010, and December 31, 2017, with no history of hypogonadism or testosterone therapy in the preceding 12 months. We matched this cohort to 53,888 men with 14 or fewer days of opioid prescriptions based on age, opioid initiation date, opioid indication, and comparable exclusion criteria. We assessed whether men, 14 or fewer days after initiation of opioid treatment, received a serum testosterone test, a diagno

SUBMITTER: Baillargeon J 

PROVIDER: S-EPMC6713891 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature